Ludwig Files A Patent That Could Be a Major Technology Breakthrough in Healthcare

Ludwig Files A Patent That Could Be a Major Technology Breakthrough in Healthcare

Ludwig Enterprises Files Messenger Ribonucleic Acid (mRNA) Patent - Ludwig mRNA Inflammatory Index™

SPARKS, NV -- September 22, 2022 -- InvestorsHub NewsWire -- (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has filed a patent on proprietary technology, the "Ludwig mRNA Inflammatory Index™." The patent covers the application of messenger ribonucleic acid (mRNA) in diagnosing, managing, and evaluating inflammatory disease patient treatment response in heart disease, diabetes, autoimmune disease, preeclampsia, and bladder, colon, and breast cancer.

"The cutting-edge technology described in this patent has the potential to help people live a healthier and longer life," stated Marvin S. Hausman, MD, Chairman of the Ludwig Scientific Advisory Board (SAB). "The patent covers the company's proprietary testing methods that can measure genetic inflammatory biomarkers for diseases like heart disease, preeclampsia, or cancer. These diseases are often silent and asymptomatic before raising their 'ugly head.' The Ludwig technology has the potential to predict disease development and allow doctors to monitor a patient's response and modify treatment steps as needed."

The molecule mRNA carries genetic information needed to produce proteins by cells. Because the data in DNA cannot be decoded directly into proteins, it is first transcribed or copied into mRNA. Each molecule of mRNA encodes the information for one protein. The mRNA molecules are transported through a cell's outer envelope into the cytoplasm, where they are translated by the rRNA of ribosomes, cellular structures which perform biological protein synthesis. Specific amounts of amino acids in a protein and their sequence determine the protein's unique properties; for example, muscle protein and hair protein contain the same 20 amino acids, but the sequences of these amino acids in the two proteins are quite different. Segments of mRNA are like a written message, and these "words" are translated into specific amino acids that make up protein. An example is mRNA vaccines that teach our cells how to make a protein that will trigger an immune response inside our bodies. Like all vaccines, mRNA vaccines benefit people who get vaccinated by protecting against diseases like COVID-19 without risking the potentially severe consequences of getting sick.

The Ludwig mRNA Inflammatory Index™ will be used in the recent announcement: "Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study.

Clinically, high-risk non-muscle-invasive bladder cancer (NMIBC) is treated with adjuvant intravesical instillations of Bacillus Calmette–Guérin (BCG) after surgery to eradicate residual disease and hence reduce the frequency of recurrence and progression (Babjuk, 2017; Lindskrog, 2021).

The Ludwig proprietary "Index" has the potential to create a genetic signature in patients with bladder cancer. This genetic signature provides a potential framework in bladder cancer clinical trials to optimize early diagnosis and clinical management with anticancer therapy.

The market for this advanced early detection system is also virtually untapped, with little competition in the billion-dollar healthcare industry. Ludwig can use these cutting-edge technologies to help people live longer, healthier lives by providing sensitive testing methods that have the potential to detect genetic markers of inflammation in diseases, such as heart disease or cancer, before there are obvious symptoms. Doctors can potentially monitor and modify a patient's positive or negative response in the treatment process - potentially saving billions in chronic disease healthcare costs.

* Babjuk, M. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 71, 447–461 (2017). * Lindskrog, S.V. et al. 2021. The integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle invasive bladder cancer. Nature Communications. 12:2301.

About Ludwig Enterprises, Inc.: Advancements in medical technology have awarded us with cutting-edge genetic tools, unheard-of even a generation ago. These genetic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genetic methodology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage disease before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry billions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig is poised to significantly impact how we think about disease and live longer, healthier lives. More Info: http://www.ludwigent.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements are not a guarantee of future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately priced, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises,

Anne Blackstone,

786-235-9026

HQ@ludwigent.com

SOURCE: Ludwig Enterprises, Inc.

Ludwig Enterprises (PK) (USOTC:LUDG)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024